免疫チェックポイント阻害剤は,がん患者の周周動脈疾患と関連しています
Jason S Chwa1, Alexander T Hong1, Forest Lin2
1Keck School of Medicine, University of Southern California, Los Angeles, CA.
Journal of vascular surgery
|February 13, 2026
まとめ
免疫チェックポイント阻害剤 (ICI) は,がん患者,特に既存の血管疾患を有する患者の周辺動脈疾患 (PAD) の高リスクに関連しています. これは,ICIを受けている患者のPADのモニタリングの必要性を強調しています.
科学分野:
- 腫瘍学 腫瘍学
- 心臓病学 心臓病学
- 免疫学 免疫学とは
背景:
- 免疫チェックポイント阻害剤 (ICI) は,がん治療に変革をもたらしました.
- ICIの心血管リスクは知られていますが,外周動脈疾患 (PAD) との関連性は不明です.
研究 の 目的:
- 癌患者のICI治療とPAD,慢性四肢脅威性イシュケミア (CLTI),または下肢切断 (LEA) の関連性を調査する.
主な方法:
- TriNetX.を使用した遡及的多センターコホート研究.
- 66,766人のICI治療患者と66,766人の対照群の傾向スコアマッチング (1:1)
- カプラン・マイヤー分析とコックスモデルでは,PAD,CLTI,LEAを含む5年間の結果を評価した.
主要な成果:
- ICI治療は,PADのリスクが著しく増加した (HR 1.59) と関連していました.
- PADリスクの増加は,すべてのICIクラス (PD-1,PD-L1,CTLA-4阻害剤) で観察されました.
- リスクの高い患者では,ICIの使用は,LEAのリスクを増加させました (HR 1.85).
結論:
- ICI治療は,がん患者のPADとLEAのリスクの増加と関連しています.
- 以前から血管の危険因子がある患者は特に脆弱です.
- 血管の評価とモニタリングは,ICI治療を受けている患者にとって非常に重要です.
関連する概念動画
Peripheral Artery Disease I: Introduction
400
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
400
Peripheral Artery Disease IV: Nursing Management
398
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
398
Peripheral Artery Disease III: Interprofessional Care
374
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
374
Peripheral Artery Disease V: Postoperative Nursing Management
426
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
426
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
461
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
461
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
630
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
630


